Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Long term follow-up of patients with recurrent ovarian cancer after Ad p53 gene replacement with SCH 58500

Cancer Gene Therapy volume 9, pages 567–572 (2002)Cite this article

Abstract

Objective: We have previously reported the safety, efficient gene transfer, and favorable CA125 responses of individuals with recurrent ovarian cancer treated by p53 gene replacement with the adenoviral vector SCH 58500. The purpose of the present investigation was to evaluate the long-term follow-up of these heavily pretreated patients subsequent to SCH 58500 dosing. Methods: Patients (n=36) were treated with either single-dose SCH 58500 in the phase I study or with multiple doses (MD) of SCH 58500 over multiple cycles in combination of platinum-based chemotherapy in the phase I/II portion of the study. Five patients were initially treated in the single-dose group and re-enrolled in the MD group. The MD group was evaluated both without the re-enrolled patients as MD1 (n=19), and as MD2 (n=24), which included them. Patients who were only treated on the single-dose arm were designated as SD (n=12). Most patients received additional chemotherapy at the discretion of their physicians on completion of the trial. The current analysis is a retrospective sequential cohort survival analysis. Results: The first patient was treated in March 1997 and the last patient completed SCH 58500 in September 1998. There was no difference in age at diagnosis, Karnofsky performance status, interval between diagnosis to SCH 58500, prior cycles or regimen of chemotherapy, platinum-free interval, percent platinum refractory patients, pretreatment CA125, or largest tumor volume between groups. Both MD groups had a slightly longer chemotherapy-free interval before SCH 58500 than the SD group. Median survival of individuals who received MD SCH 58500 with chemotherapy was 12–13.0 months, compared to only 5 months for those treated with SD SCH 58500. There are 10 long-term survivors more than 20 months after MD treatment for recurrent disease compared to only 2 long-term survivors after SD SCH 58500. Conclusion: The 12- to 13.0-month median survival in a heavily pretreated population with recurrent ovarian cancer compares favorably to the 16-month median survival for individuals treated with paclitaxel at the time of initial recurrence of this disease and is more than double the 5-month survival seen with palliative radiotherapy or paclitaxel failure. These data suggest that further study of SCH58500 is clearly indicated.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2

Similar content being viewed by others

References

  1. Markman M, Hakes T, Reichman B et al. Ifosfamide and mesna in previously treated advanced epithelial ovarian cancer: activity in platinum-resistant disease J Clin Oncol 1992 10: 243–248

    Article  CAS  PubMed  Google Scholar 

  2. Tenbokkel Huinink W, Gore M, Carmichael J et al. Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer J Clin Oncol 1997 15: 2183–2193

    Article  CAS  Google Scholar 

  3. Israel VP, Garcia AA, Roman L et al. Phase II study of liposomal doxorubicin in advanced gynecologic cancers Gynecol Oncol 2000 78: 143–147

    Article  CAS  PubMed  Google Scholar 

  4. Thigpen JT, Blessing JA, Ball H et al. Phase II trial of paclitaxel in patients with progressive ovarian carcinoma after platinum-based chemotherapy: a gynecologic oncology group study J Clin Oncol 1994 12: 1748–1753

    Article  CAS  PubMed  Google Scholar 

  5. Aunoble B, Sanches R, Didier E et al. Major oncogenes and tumor suppressor genes involved in epithelial ovarian cancer Int J Oncol 2000 16: 567–576

    CAS  PubMed  Google Scholar 

  6. Lynch HT, Casey MJ, Lynch J et al. Genetics and ovarian carcinoma Semin Oncol 1998 25: 265–280

    CAS  PubMed  Google Scholar 

  7. Griffiths CT . Surgical resection of tumor bulk in the primary treatment of ovarian carcinoma Natl Cancer Inst Monogr 1975 42: 101–104

    CAS  PubMed  Google Scholar 

  8. Hoskins WJ, Rubin SC, Dulaney E et al. Influence of secondary cytoreduction at the time of second-look laparotomy on the survival of patients with epithelial ovarian carcinoma Gynecol Oncol 1989 34: 365–372

    Article  CAS  PubMed  Google Scholar 

  9. Hoskins WJ, McGuire WP, Brady MF et al. The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma Am J Obstet Gynecol 1994 170: 974–979

    Article  CAS  PubMed  Google Scholar 

  10. Jänicke F, Hölscher M, Juhn W et al. Radical surgical procedure improves survival time in patients with recurrent ovarian cancer Cancer 1992 70: 2129–2136

    Article  PubMed  Google Scholar 

  11. Sood AK, Sorosky J, Dolan M et al. Distant metastases in ovarian cancer: why do they occur? Clin Cancer Res 1999 5: 2485–2490

    CAS  PubMed  Google Scholar 

  12. Geisler J, Geisler H . Brain metastases in epithelial ovarian carcinoma Gynecol Oncol 1995 57: 246–249

    Article  CAS  PubMed  Google Scholar 

  13. Shahin MS, Hughes JH, Sood AK et al. The prognostic significance of p53 tumor suppressor gene alterations in ovarian carcinoma Cancer 2000 89: 2006–2017

    Article  CAS  PubMed  Google Scholar 

  14. Buller RE, Runnebaum IB, Karlan B et al. A phase I/II trial of rAd/p53 (SCH 58500) gene replacement in recurrent ovarian cancer Cancer Gene Ther 2002 9: 553–566

    Article  CAS  PubMed  Google Scholar 

  15. Wills KN, Maneval DC, Menzel P et al. Development and characterization of recombinant adenoviruses encoding human p53 for gene therapy of cancer Hum Gene Ther 1994 5: 1079–1088

    Article  CAS  PubMed  Google Scholar 

  16. Markman M, Iseminger KA, Hatch KD et al. Tamoxifen in platinum-refractory ovarian cancer: a gynecologic oncology group ancillary report Gynecol Oncol 1996 62: 4–6

    Article  CAS  PubMed  Google Scholar 

  17. Gershenson DM, Kavanagh JJ, Copeland LJ et al. Re-treatment of patients with recurrent epithelial ovarian cancer with cisplatin-based chemotherapy Obstet Gynecol 1989 73: 798–802

    CAS  PubMed  Google Scholar 

  18. Gore ME, Fryatt I, Wiltshaw E et al. Treatment of relapsed carcinoma of the ovary with cisplatin or carboplatin following initial treatment with these compounds Gynecol Oncol 1990 36: 207–211

    Article  CAS  PubMed  Google Scholar 

  19. van der Burg MEL, Hoff AM, van Lent M et al. Carboplatin and cyclophosphamide salvage therapy for ovarian cancer patients relapsing after cisplatin combination chemotherapy Eur J Cancer 1991 27: 250–253

    Article  Google Scholar 

  20. Vergote I, Himmelman A, Frankendal B et al. Hexamethylmelamine as second-line therapy in platin-resistant ovarian cancer Gynecol Oncol 1992 47: 282–286

    Article  CAS  PubMed  Google Scholar 

  21. Rosen GF, Lurain JR, Newton M . Hexamethylmelamine in ovarian cancer after failure of cisplatin-based multiple-agent chemotherapy Gynecol Oncol 1987 27: 173–179

    Article  CAS  PubMed  Google Scholar 

  22. Markman M, Rothman R, Hakes T et al. Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin J Clin Oncol 1991 9: 389–393

    Article  CAS  PubMed  Google Scholar 

  23. Eisenhauer EA, Huinink WW ten Bokkel, Swenerton KD et al. European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: High-dose versus low-dose and long versus short infusion J Clin Oncol 1994 12: 2654–2666

    Article  CAS  PubMed  Google Scholar 

  24. Einzig AI, Wiernik PH, Sasloff J et al. Phase II study and long-term follow-up of patients treated with taxol for advanced ovarian adenocarcinoma J Clin Oncol 1992 10: 1748–1753

    Article  CAS  PubMed  Google Scholar 

  25. Corn BW, Lanciano RM, Boente M et al. Effective radiotherapeutic palliation after chemotherapy failure Cancer 1994 74: 2979–2983

    Article  CAS  PubMed  Google Scholar 

  26. Buller RE, Skilling JS, Sood AK et al. Field cancerization: why late “recurrent” ovarian cancer is not recurrent Am J Obstet Gynecol 1998 178: 641–649

    Article  CAS  PubMed  Google Scholar 

  27. Buller RE, Shahin M, Karlan B et al. Multidose intraperitoneal (IP) rad/p53 (SCH 58500) gene replacement combined with chemotherapy in heavily pretreated recurrent ovarian cancer is associated with prolonged survival Proc Am Soc Clin Oncol 2001 20: 262a

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, The University of Iowa Hospitals and Clinics, Iowa City, 52242-1009, Iowa, USA

    Richard E Buller, Mark S Shahin & Vikas Mahavni

  2. Schering-Plough Research Institute, Kenilworth, New Jersey, USA

    Jo Ann Horowitz & Stan Petrauskas

  3. University of Freiburg, Freiburg, Germany

    Ingo B Runnebaum & Rolf Kreienberg

  4. University of Ulm, Ulm, Germany

    Ingo B Runnebaum & Rolf Kreienberg

  5. University of California, Los Angeles, California, USA

    Beth Karlan, Dennis Slamon & Mark Pegram

Authors
  1. Richard E Buller
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mark S Shahin
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jo Ann Horowitz
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Ingo B Runnebaum
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Vikas Mahavni
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Stan Petrauskas
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Rolf Kreienberg
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Beth Karlan
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Dennis Slamon
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Mark Pegram
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Richard E Buller.

Additional information

Presented in part at the 9th International Conference on Gene Therapy of Cancer, San Diego, CA December 7–9, 2000.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Buller, R., Shahin, M., Horowitz, J. et al. Long term follow-up of patients with recurrent ovarian cancer after Ad p53 gene replacement with SCH 58500. Cancer Gene Ther 9, 567–572 (2002). https://doi.org/10.1038/sj.cgt.7700473

Download citation

  • Received:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.cgt.7700473

Keywords

This article is cited by

Search

Advanced search

Quick links